anti-SBR responses can be induced. 1 Moreover, an adjuvant amount of intact CT can further increase the mucosal immunogenicity of the SBR-CTA2/B chimeric protein. In the present study, we investigated if the mucosal immunogenicity of SBR-CTA2/B can be potentiated with the safe systemic adjuvant monophosphoryl lipid A (MPL ® ). 2 Groups of BALB/c mice were immunized by the intranasal (i.n.) route three times at 14 day intervals with: (i) SBR; (ii) SBR + MPL aqueous formulation (MPL-AF); (iii) SBR-CTA2/B; (iv) SBR-CTA2/B + MPL-AF; and (v) an unrelated antigen, tetanus toxoid (TT) + MPL-AF, as control. The SBR and TT were used at 20 µg/dose, the SBR-CTA2/B at an equivalent 50 µg/dose, and MPL-AF at 25 µg/dose. Biological samples (serum, saliva, and vaginal secretion) were collected at days 0, 14, 28, 36, 43, and 120, and analyzed for the presence of anti-SBR antibodies by ELISA.
Mice given SBR + MPL-AF, SBR-CTA2/B, or SBR-CTA2/B + MPL-AF by the i.n. route had high anti-SBR responses in serum, saliva, and vaginal secretions which generally peaked 2 weeks after the third immunization (Table 1 ) and persisted at substantial levels until at least day 120. Low levels of anti-SBR activity were detected in mice given SBR alone, whereas no specific anti-SBR antibodies were detected in mice immunized with TT + MPL-AF ( Table 1 ). The co-administration of MPL-AF with either SBR or SBR-CTA2/B resulted in significantly higher (P < 0.05) serum IgG and mucosal IgA responses to SBR than those induced by SBR-CTA2/B alone, but there were no significant differences between the groups given MPL-AF regardless of the form (free or CTA2/Blinked) of SBR. These data show that MPL-AF, is a potent mucosal adjuvant when given by the i.n. route which may be useful in vaccines against caries, sexually-transmitted diseases, and possibly other infectious diseases. Samples were collected 2 weeks after the third immunization (day 43). Values are geometric mean ± SD of 6 mice.
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Phagocytosis by macrophages can be mediated via plasma membrane receptors for opsonins (subclasses of IgG, IgA, complement-derived proteins, fibronectin, collectins) or by direct recognition of ligands. 1 The latter, so-called pattern recognition receptors, include scavenger receptors for a range of polyanionic ligands, 2 and mannose receptors, for mannosylated and other selected glycoconjugates. 3 Such ligands are found on microorganisms as well as on modified or natural host molecules and cells. The scavenger receptors were originally described by Brown and Goldstein as responsible for foam cell formation, in which macrophages accumulated modified low density lipoproteins. Two SR-A type II membrane glycoprotein isoforms were cloned by Krieger, Kodama, and their colleagues and implicated in uptake of acetylated LDL. The SR-A molecules were shown to be trimeric structures containing a triple helical collagenous domain, with or without extracellular C-terminal cysteine-rich domains. The SR-A molecule has been studied extensively in regard to endocytic functions and shown to bind a wide range of mostly artificial polyanionic macromolecules, including lipopolysaccharide (LPS) and lipoteichoic acid (LTA). 4 It is now clear that there are other type A SR molecules; a third SR-A isoform has been described recently, 5 and a distinct collagenous receptor, Marco, was cloned and shown to bind bacteria. 6 Additionally, there are other groups of structurally unrelated receptors which have also been considered to be SR-like receptors by virtue of polyanion-ligand binding. Several of these molecules have been implicated in the recognition and uptake of apoptotic cells. Our laboratory isolated a monoclonal antibody, 2F8 that inhibited EDTA-resistant adhesion of murine macrophages to serum-coated tissue culture plastic. 7 The antigen was shown to be SR-A (type I and II isoforms) present on the surface as well as intracellularly in many mature macrophage populations in situ and in culture, as well as in selected endothelial cells, e.g. in liver. 8 Since 2F8 antigen expression appeared relatively early in macrophage ontogeny, and was broadly expressed by tissue macrophages, it seemed likely that the SR-A molecule contributed to host defense, as well as atherogenesis, as also suggested by others.
The development of the SR-A knockout mouse by Kodama, Suzuki, and colleagues confirmed that 2F8 antigen was encoded by SR-A, and that the molecule contributed to adhesion in vitro, endocytosis of acetylated LDL, as well as of oxidised LDL and AGE-modified protein. 9 SR-A mice crossed with Apo E-deficient mice showed reduced foam cell-rich lesions in the arterial wall. In addition, SR-A knockout mice were deficient in resistance to Listeria monocytogenes infection. Macrophages from SR-A knockout mice displayed only 50% of the phagocytic uptake of apoptotic thymocytes, in vitro, compared with macrophages from wild type controls. 10 However, there was no phenotype of apoptotic cell clearance in SR-A knockout mice in vivo, suggesting that other SR-like molecules could compensate for this function (N. Platt, unpublished observations).
SR-A knockout mice were not immunodeficient upon challenge with viable BCG. 11 Macrophage-rich granulomata were found normally (although possibly with delayed kinetics) 9 and the macrophages were induced to express Ia (MHC-class II antigens), indicating that they were immunologically primed, presumably by interferon-γ. BCG-primed animals became more sensitive to LPS challenge and SR-A knockout mice exhibited a ~10fold increase in susceptibility to LPS-induced shock. This was mediated mainly by TNFα, which appeared rapidly and at greatly enhanced levels in the circulation after challenge. Other cytokines, such as IL-6, were also elevated in plasma. We proposed that SR-A limits TNFα release by primed/activated macrophages, which utilise CD14 and LPS binding protein as the major pathway for cytokine induction. Other receptors are likely to play a similar role, including Marco, also induced by BCG infection, and possibly CR3. Whether the action of SR-A is primarily through LPS clearance or by down-regulation of LPS-induced signalling is still unclear.
To demonstrate that SR-A is able to bind and ingest intact bacteria, we studied the uptake of FITC-labelled Escherichia coli and Staphylococcus aureus by BCGactivated peritoneal macrophages from SR-A knockout and control mice, using a FACS-based assay. 12 A partial deficiency in uptake of both organisms was observed in either the presence or absence of serum opsonins. The SR-A, therefore, contributes directly to bacterial recognition and uptake, consistent with the reported in vivo results.
In order to study the recognition and phagocytic role of SR-A by itself, in the context of cells which are not professional phagocytes, we have utilised CHO cells transfected with either SR-A I or II isoforms. We observed receptor-specific binding and ingestion by these transfectants, although transfected cells are less efficient than primary macrophages or macrophage-like cell lines with regard to phagocytosis (L. Peiser & P. Gough, unpublished observations).
Dendritic cells (DC) are other macrophage-related cells, which are especially important in antigen recognition, processing, and presentation. DC produced in cell culture from murine bone marrow precursors in the presence of GM-CSF, expressed authentic SR-A, as shown by FACS analysis of cells from SR-A knockout and control mice. 12 The SR-A of these mainly immature DC was functional in that acetylated LDL was taken up by wild type cells and inhabitable by 2F8 antibodies, which reduced uptake to levels displayed by SR-A knockout cells. The ability of DC to take up bacteria is under study, and is particularly pertinent to the potential immunogenic role of DC in response to infection. Other studies in progress are investigating the nature of the ligands detected by SR-A in the intact organism, and the role of SR-A in differential induction of inflammatory mediators by macrophages and DC in response to micro-organisms versus apoptotic cells.
